The official Drugs@FDA dataset lists original submission 1 for NDA 209637 with status AP dated 2017-12-05, and names semaglutide among the application record's active ingredients.
The Federal Register published notice 2017-25920, attributed to FDA and its parent HHS department, on 2017-12-01. Its official title is “Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.
DailyMed lists Structured Product Labeling version 17 for the reviewed Linaclotide label family with a published date of 2017-11-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 25 for the reviewed Dulaglutide label family with a published date of 2017-10-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 209210 with status AP dated 2017-10-20, and names exenatide synthetic among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 5 for the reviewed Lixisenatide label family with a published date of 2017-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Abaloparatide label family with a published date of 2017-10-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The Federal Register published notice 2017-21202, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide and Teriparatide.
DailyMed lists Structured Product Labeling version 4 for the reviewed Lixisenatide label family with a published date of 2017-09-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 23 for the reviewed Dulaglutide label family with a published date of 2017-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 22 for the reviewed Dulaglutide label family with a published date of 2017-08-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 16 for the reviewed Linaclotide label family with a published date of 2017-07-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 21 for the reviewed Dulaglutide label family with a published date of 2017-06-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 15 for the reviewed Linaclotide label family with a published date of 2017-06-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.
DailyMed lists Structured Product Labeling version 14 for the reviewed Linaclotide label family with a published date of 2017-06-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2017-10326, attributed to FDA and its parent HHS department, on 2017-05-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
DailyMed lists Structured Product Labeling version 1 for the reviewed Abaloparatide label family with a published date of 2017-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 208743 with status AP dated 2017-04-28, and names abaloparatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 13 for the reviewed Linaclotide label family with a published date of 2017-02-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 19 for the reviewed Dulaglutide label family with a published date of 2017-02-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 208745 with status AP dated 2017-01-19, and names plecanatide among the application record's active ingredients.